drugset / Trial / NCT02607111
A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients
Phase 4
Completed
15 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NaSingle-groupOpen-labelPrevention
Summary
This study evaluates the optimal dosage and safety of Dalteparin when used as an anticoagulant for hemodialysis therapies.
Timeline
- Start
- 2016-08
- Primary completion
- 2018-07
- Completion
- 2018-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalteparin sodium | Other / unclassified | — | Other |